Protective effect of n-acetyl-L-cysteine and rosuvastatin against oxidative stress in fibroblasts from asymptomatic patients with X-ALD: a preliminary study

Introduction: Several studies in the literature have evaluated the role of oxidative stress and adjuvant therapies for X-linked adrenoleukodystrophy (X-ALD). Here, we investigated whether n-acetyl-L-cysteine (NAC) and rosuvastatin (RSV) could influence the generation of reactive species, redox status and nitrative stress in fibroblasts from asymptomatic patients with X-ALD. Methods: Skin biopsy samples were cultured and treated for 2 hours (37 °C) with NAC and RSV.Results: X-ALD fibroblasts generated high levels of reactive oxygen species. These levels were significantly lower in fibroblasts treated with NAC and RSV relative to untreated samples. The X-ALD fibroblasts from asymptomatic patients also had higher catalase activity, and only NAC was able to increase enzyme activity in the samples.Conclusion: Our results indicated that NAC and RSV were able to improve oxidative stress parameters in fibroblasts from asymptomatic patients with X-ALD, showing that adjuvant antioxidant therapy may be a promising treatment strategy for asymptomatic patients with this disease

Diagnóstico pré-natal: avanços e perspectivas

OBJECTIVE: The development of laboratorial techniques for the prenatal diagnosis of genetic diseases was a great step for clinical genetics, changing reproductive perspectives of high risk families. At Hospital de Clínicas de Porto Alegre (HCPA), the prenatal diagnosis program is part of the Fetal Medicine Group, which includes several professionals of different areas. The main objective of this group is to study, evaluate, diagnose and advice high risk pregnant women. The aim of the present study is to review the main procedures for the prenatal diagnosis and to show the results of our sample regarding the laboratory analysis offer to the pregnant women. MATERIALS AND METHODS: From January 1989 to July 2001, karyotypes were performed for 613 pregnancies, metabolic studies were carried out in 86 pregnancies and molecular analysis was performed for four cases. Prenatal genetic counseling was given to 1,378 families. RESULTS: The prenatal diagnosis of genetic diseases accomplished at HCPA reached a culture growth rate of 98%, which is similar to the result of developed countries. CONCLUSIONS: The prenatal diagnosis is an important tool for the families that are likely to have fetal anomalities. New techniques of diagnosis are being introduced at HCPA, and they will contribute even more to the treatmento of these families. Future prospectives and ethical aspects for prenatal diagnosis are also discussed.OBJETIVO: O desenvolvimento de técnicas para diagnosticar as condições genéticas intra-útero foi um grande avanço na genética clínica, mudando a perspectiva reprodutiva de famílias de risco. No Hospital de Clínicas de Porto Alegre (HCPA), o programa de diagnóstico pré-natal (DPN) de anomalias congênitas faz parte do Grupo de Medicina Fetal, que é composto por uma equipe multidisciplinar, cuja meta principal é estudar, analisar, diagnosticar e aconselhar as gestantes de alto risco. O trabalho apresentado aqui tem como objetivos revisar os principais procedimentos de diagnóstico pré-natal, descrever a nossa amostra e os exames que são oferecidos às nossas gestantes. MATERIAIS E MÉTODOS: De janeiro de 1989 a julho de 2001, foram cariotipadas 613 gestações, realizadas investigações enzimáticas em 86 casos e em 4 foram realizados estudos moleculares em material fetal. Um total de 1.378 novos casos foram avaliados no ambulatório de DPN do HCPA, de julho de 1993 a julho de 2001, para aconselhamento genético reprodutivo. RESULTADOS: O diagnóstico pré-natal de cromossomopatias realizado no HCPA atingiu uma taxa de crescimento de culturas de 98%, índice semelhante ao dos paísesdesenvolvidos. CONCLUSÕES: O diagnóstico pré-natal é um importante recurso para as famílias com risco de anomalia fetal. Novas técnicas de diagnóstico estão em implantação no HCPA, e poderão contribuir ainda mais para o atendimento dessas famílias. Apresentamos também os aspectos éticos envolvidos e algumas perspectivas futuras na área do diagnóstico pré-natal de anormalidades congênitas

Prenatal diagnosis of fetal chromosomal abnormalities: report of an 18-year experience in a Brazilian public hospital

The study of the fetal karyotype became an important tool for the fetal diagnosis of genetic diseases in the 1970s. Although application of this test has remained very restricted in Brazil, we had 905 referrals for prenatal fetal karyotyping between 1989 and 2007. In 879 cases, a fetal karyotype was obtained. We detected 74 abnormal karyotypes (8.4%), the majority being found when the prior indication was fetal malformation. When obtaining amniotic fluid or chorionic villus samples was difficult, alternative fetal materials (urine, cystic hygroma, cystic lung, intreperitoneal and cerebrospinal fluids) were collected and we had success in obtaining karyotypes in all 13 cases. Although, the option of terminating abnormal pregnancies does not legally exist in Brazil, the information gained in assessing the prognosis of on-going pregnancies or estimating recurrence risks justifies prenatal diagnosis of chromosome abnormalities. We conclude that, in keeping with the policy in most other countries, prenatal cytogenetic analysis is strongly recommended in high-risk pregnancies for fetal abnormalities. However, the unique aspect of this type of study is not its rarity in world terms, but its rarity in Brazil. This argues that Brazilian health policy on prenatal diagnosis requires reforming to make it much more widely available within the public health care sector

Diagnóstico pré-natal: avanços e perspectivas

OBJECTIVE: The development of laboratorial techniques for the prenatal diagnosis of genetic diseases was a great step for clinical genetics, changing reproductive perspectives of high risk families. At Hospital de Clínicas de Porto Alegre (HCPA), the prenatal diagnosis program is part of the Fetal Medicine Group, which includes several professionals of different areas. The main objective of this group is to study, evaluate, diagnose and advice high risk pregnant women. The aim of the present study is to review the main procedures for the prenatal diagnosis and to show the results of our sample regarding the laboratory analysis offer to the pregnant women. MATERIALS AND METHODS: From January 1989 to July 2001, karyotypes were performed for 613 pregnancies, metabolic studies were carried out in 86 pregnancies and molecular analysis was performed for four cases. Prenatal genetic counseling was given to 1,378 families. RESULTS: The prenatal diagnosis of genetic diseases accomplished at HCPA reached a culture growth rate of 98%, which is similar to the result of developed countries. CONCLUSIONS: The prenatal diagnosis is an important tool for the families that are likely to have fetal anomalities. New techniques of diagnosis are being introduced at HCPA, and they will contribute even more to the treatmento of these families. Future prospectives and ethical aspects for prenatal diagnosis are also discussed.OBJETIVO: O desenvolvimento de técnicas para diagnosticar as condições genéticas intra-útero foi um grande avanço na genética clínica, mudando a perspectiva reprodutiva de famílias de risco. No Hospital de Clínicas de Porto Alegre (HCPA), o programa de diagnóstico pré-natal (DPN) de anomalias congênitas faz parte do Grupo de Medicina Fetal, que é composto por uma equipe multidisciplinar, cuja meta principal é estudar, analisar, diagnosticar e aconselhar as gestantes de alto risco. O trabalho apresentado aqui tem como objetivos revisar os principais procedimentos de diagnóstico pré-natal, descrever a nossa amostra e os exames que são oferecidos às nossas gestantes. MATERIAIS E MÉTODOS: De janeiro de 1989 a julho de 2001, foram cariotipadas 613 gestações, realizadas investigações enzimáticas em 86 casos e em 4 foram realizados estudos moleculares em material fetal. Um total de 1.378 novos casos foram avaliados no ambulatório de DPN do HCPA, de julho de 1993 a julho de 2001, para aconselhamento genético reprodutivo. RESULTADOS: O diagnóstico pré-natal de cromossomopatias realizado no HCPA atingiu uma taxa de crescimento de culturas de 98%, índice semelhante ao dos paísesdesenvolvidos. CONCLUSÕES: O diagnóstico pré-natal é um importante recurso para as famílias com risco de anomalia fetal. Novas técnicas de diagnóstico estão em implantação no HCPA, e poderão contribuir ainda mais para o atendimento dessas famílias. Apresentamos também os aspectos éticos envolvidos e algumas perspectivas futuras na área do diagnóstico pré-natal de anormalidades congênitas

Protective effect of n-acetyl-L-cysteine and rosuvastatin against oxidative stress in fibroblasts from asymptomatic patients with X-ALD: a preliminary study

Introduction: Several studies in the literature have evaluated the role of oxidative stress and adjuvant therapies for X-linked adrenoleukodystrophy (X-ALD). Here, we investigated whether n-acetyl-L-cysteine (NAC) and rosuvastatin (RSV) could influence the generation of reactive species, redox status and nitrative stress in fibroblasts from asymptomatic patients with X-ALD. Methods: Skin biopsy samples were cultured and treated for 2 hours (37 °C) with NAC and RSV.Results: X-ALD fibroblasts generated high levels of reactive oxygen species. These levels were significantly lower in fibroblasts treated with NAC and RSV relative to untreated samples. The X-ALD fibroblasts from asymptomatic patients also had higher catalase activity, and only NAC was able to increase enzyme activity in the samples.Conclusion: Our results indicated that NAC and RSV were able to improve oxidative stress parameters in fibroblasts from asymptomatic patients with X-ALD, showing that adjuvant antioxidant therapy may be a promising treatment strategy for asymptomatic patients with this disease

LC/MS/MS measurement of glycosaminoglycans in amniotic fluid of a MPS VII fetus

sem informação1201-2S77S77sem informaçãosem informação13. Annual Research Meeting on We're Organizing Research for Lysosomal Diseases (WORLD)FEB 13-17, 2017San Diego, C